Thyroid Lymphoma Medication

Updated: May 09, 2022
  • Author: Mohammad Muhsin Chisti, MD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Medication Summary

Treatment for large-cell lymphoma is selected on the basis of prognostic factors. Most investigators treat patients whose International Prognostic Index (IPI) result is favorable by using the standard CHOP (cyclophosphamide, doxorubicin [hydroxydaunorubicin], vincristine [Oncovin], prednisone) regimen or rituximab plus CHOP (R-CHOP), followed by irradiation consolidation in patients with Ann Arbor stages I-II. Three to six courses of chemotherapy are administered.

In general, the addition of rituximab provides benefit in survival and disease-free survival rates, and the results are also assumed to apply to primary thyroid large-cell lymphomas.

Intrathecal methotrexate is also used in patients with central nervous system involvement.

Regimens used in refractory or recurrent cases include the following:

  • GEMOX (gemcitabine and oxaliplatin)
  • MINE (mesna, ifosfamide, mitoxantrone, etoposide)
  • ESHAP (etoposide, methylprednisolone, cisplatin, cytarabine)